Healthtech Startup Dectrocel Secures Funding to Expand AI Diagnostic Platform DecXpert

The newly raised capital will be used to scale commercial deployment across India, deepen partnerships with original equipment manufacturers (OEMs), and support geographic expansion into Southeast Asia.

Lucknow-based healthtech startup Dectrocel has secured ₹4 Cr in fresh funding to scale deployment of its AI-powered diagnostic platform DecXpert and expand into new imaging modalities.

The funding round was led by the IAN Group–powered BioAngels, with participation from PadUp Ventures and Vinners. Named investors in the round included IAN members Nitin Zamre, Samir Kalia and Mitesh Shah.

Founded in 2020 by Ankit Shukla, Saumya Shukla and Nikhil Mishra, Dectrocel develops AI-driven diagnostic solutions for radiology. Its flagship product, DecXpert, is designed as a clinical decision support platform capable of interpreting chest X-rays and CT scans.

According to the statements, the newly raised capital will be used to scale commercial deployment across India, deepen partnerships with original equipment manufacturers (OEMs), and support geographic expansion into Southeast Asia.

Funds will also be directed toward product development, specifically adding new modules to the DecXpert platform and enhancing its multimodal self-learning AI capabilities.

Dectrocel’s DecXpert has undergone independent clinical validation. A peer-reviewed multicentre study published in Scientific Reports (Nature portfolio) evaluated DecXpert version 1.4 for tuberculosis detection in chest radiographs across more than 4,300 participants in northern India.

The study reported sensitivity of approximately 88 percent and specificity of 85 percent when benchmarked against the GeneXpert MTB/RIF assay, with an area under the curve (AUC) of 0.91 when demographic variables were included. These metrics position the software as a credible tool for TB screening in clinical and public health settings.

Reportedly, DecXpert has received regulatory approval for clinical use in India from the Central Drugs Standard Control Organization (CDSCO).

However, a specific approval certificate or listing has not been publicly located in CDSCO’s registries.

Moreover, Dectrocel has also claimed that DecXpert delivers “10x faster” readings and “98 percent accuracy” in chest imaging.

These claims differ from the diagnostic performance metrics detailed in the peer-reviewed study.

While the published sensitivity and specificity suggest strong potential, they fall short of the unqualified “98 percent accuracy” claim and should be considered the more reliable evidence.

The startup is positioning its product for India’s underserved radiology market, estimated at around ₹1,000 Cr for digital X-rays, where shortages of radiologists remain a significant challenge.

Dectrocel intends to use OEM partnerships to embed DecXpert into hospital and diagnostic workflows, while simultaneously building presence in Southeast Asian markets.

With the capital infusion, the startup now faces the task of converting early validation results and investor confidence into sustainable clinical and commercial traction across India and abroad.

Stay tuned for more such updates on Digital Health News